Your browser doesn't support javascript.
loading
Bacterial production and biophysical characterization of a hard-to-fold scFv against myeloid leukemia cell surface marker, IL-1RAP.
Farokhi-Fard, Aref; Bayat, Elham; Beig Parikhani, Arezoo; Komijani, Samira; Aghamirza Moghim Aliabadi, Hooman; Sardari, Soroush; Gharib, Behrouz; Barkhordari, Farzaneh; Azadmanesh, Kayhan; Karimipoor, Morteza; Bakhshandeh, Haleh; Davami, Fatemeh.
Afiliação
  • Farokhi-Fard A; Medical Biotechnology Department, Biotechnology research center, Pasteur Institute of Iran (IPI), No. 69, Pasteur Ave, Tehran, Iran.
  • Bayat E; Student Research Committee, Pasteur Institute of Iran, Tehran, Iran.
  • Beig Parikhani A; Medical Biotechnology Department, Biotechnology research center, Pasteur Institute of Iran (IPI), No. 69, Pasteur Ave, Tehran, Iran.
  • Komijani S; Medical Biotechnology Department, Biotechnology research center, Pasteur Institute of Iran (IPI), No. 69, Pasteur Ave, Tehran, Iran.
  • Aghamirza Moghim Aliabadi H; Medical Biotechnology Department, Biotechnology research center, Pasteur Institute of Iran (IPI), No. 69, Pasteur Ave, Tehran, Iran.
  • Sardari S; Protein Chemistry Laboratory, Medical Biotechnology Department, Biotechnology research center, Pasteur Institute of Iran, Tehran, Iran.
  • Gharib B; Advance Chemical Studies Laboratory, Faculty of Chemistry, K.N. Toosi University, Tehran, Iran.
  • Barkhordari F; Drug Design and Bioinformatics Unit, Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
  • Azadmanesh K; Oncology Department, Naft Hospital, Tehran, Iran.
  • Karimipoor M; Medical Biotechnology Department, Biotechnology research center, Pasteur Institute of Iran (IPI), No. 69, Pasteur Ave, Tehran, Iran.
  • Bakhshandeh H; Departement of Virology, Pasteur Institute of Iran, Tehran, Iran.
  • Davami F; Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Mol Biol Rep ; 50(2): 1191-1202, 2023 Feb.
Article em En | MEDLINE | ID: mdl-36435922
ABSTRACT

BACKGROUND:

Interleukin-1 receptor accessory protein (IL-1RAP) is one of the most promising therapeutic targets proposed for myeloid leukemia. Antibodies (Abs) specific to IL-1RAP could be valuable tools for targeted therapy of this lethal malignancy. This study is about the preparation of a difficult-to-produce single-chain variable fragment (scFv) construct against the membrane-bound isoform of human IL-1RAP using Escherichia coli (E. coli).

METHODS:

Different approaches were examined for refolding and characterization of the scFv. Binding activities of antibody fragments were comparatively evaluated using cell-based enzyme-linked immunosorbent assay (ELISA). Homogeneity and secondary structure of selected scFv preparation were analyzed using analytical size exclusion chromatography (SEC) and circular dichroism (CD) spectroscopy, respectively. The activity of the selected preparation was evaluated after long-term storage, repeated freeze-thaw cycles, or following incubation with normal and leukemic serum.

RESULTS:

Strategies for soluble expression of the scFv failed. Even with the help of Trx, ≥ 98% of proteins were expressed as inclusion bodies (IBs). Among three different refolding methods, the highest recovery rate was obtained from the dilution method (11.2%). Trx-tag substantially enhanced the expression level (18%, considering the molecular weight (MW) differences), recovery rate (˃1.6-fold), and binding activity (˃2.6-fold increase in absorbance450nm). The produced scFv exhibited expected secondary structure as well as acceptable bio-functionality, homogeneity, and stability.

CONCLUSION:

We were able to produce  21 mg/L culture functional and stable anti-IL-1RAP scFv via recovering IBs by pulse dilution procedure. The produced scFv as a useful targeting agent could be used in scheming new therapeutics or diagnostics for myeloid malignancies.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide / Anticorpos de Cadeia Única Limite: Humans Idioma: En Revista: Mol Biol Rep Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Irã

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide / Anticorpos de Cadeia Única Limite: Humans Idioma: En Revista: Mol Biol Rep Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Irã